18-19 August 2010, Hilton Hotel, Addis Ababa, Ethiopia.
This two-day Open Forum will be the fourth in a series of meetings aimed to raise and address key issues in TB drug development, with a special focus on regulatory affairs.

The Forum will include sessions on the current global TB drug development portfolio, key issues in the critical path to TB drug registration, designing pivotal trials, conducting registration trials in high TB burden countries, challenges in TB drug development for resistant disease and developing regimens containing multiple novel agents.

These meetings are designed to bring together regulators, TB drug developers and other interested stakeholders, such as TB care providers, public health policy-makers, and community advocates from both major industrialized and high burden countries. Open Forum 4 will have a special focus on Africa and the regulatory challenges it faces.

This meeting is supported in part by grants from AstraZeneca, Bayer Schering Pharma, Celgene, GlaxoSmithKline, Novartis International AG, Pfizer, sanofi-aventis, and Tibotec.

For further information and registration, please visit:

About TB Alliance
The Global Alliance for TB Drug Development (TB Alliance) is a not-for-profit, product development partnership accelerating the discovery and development of new tuberculosis (TB) drugs that will shorten treatment, be effective against susceptible and resistant strains, be compatible with antiretroviral therapies for those HIV-TB patients currently on such therapies, and improve treatment of latent infection. For more information, visit www.tballiance.org.